ScholarIQanswers from OpenAlex & ORCID
Lin Shen
ResearcherPublications, citations & collaboration network
Lin Shen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Lin Shen have?
ScholarIQindexed works
Lin Shen has 804 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lin Shen have?
ScholarIQcitation count
Lin Shen has 27,749 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Lin Shen?
ScholarIQh-index
Lin Shen has an h-index of 63 in OpenAlex.
What is the i10-index of Lin Shen?
ScholarIQi10-index
Lin Shen has an i10-index of 287 in OpenAlex.
What is the ORCID of Lin Shen?
ScholarIQorcid
The ORCID for Lin Shen is on the source record.
What is the OpenAlex record for Lin Shen?
ScholarIQopenalex
The OpenAlex for Lin Shen is on the source record.
What are the most-cited papers on Lin Shen?
ScholarIQmost cited works
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Xiaotian Zhang, Liang Han, Ziyu Li, Yingwei Xue, Yanong Wang, Zhiwei Zhou, Jiren Yu, Zhaode Bu, Lin Chen, Yian Du, Xinbao Wang, Aiwen Wu, Guoli Li, Xiangqian Su, Gang Xiao, Ming Cui, Dan Wu, Li Chen, Xiaojiang Wu, Yanbing Zhou, Lianhai Zhang, Chengxue Dang, Yulong He, Zhongtao Zhang, Yihong Sun, Yong Li, Huanqiu Chen, Yuxian Bai, Changsong Qi, Peiwu Yu, Guanbao Zhu, Jian Suo, Baoqing Jia, Leping Li, Ze-Ning Huang, Fei Li, Yingjiang Ye, Huimian Xu, Xin Wang, Yannan Yuan, E Jian‐Yu, Xiangji Ying, Chen Yao, Lin Shen, Jiafu Ji
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng, Qi Li, Nong Xu, Xichun Hu, Wangjun Liao, Yi Jiang, Xiaoyan Lin, Qingyuan Zhang, Xianglin Yuan, Haixin Huang, Ye Chen, Guanghai Dai, Jianhua Shi, Lin Shen, Shujun Yang, Yongqian Shu, Yunpeng Liu, Weifeng Wang, Hai Wu, Hui Feng, Sheng Yao, Rui‐Hua Xu
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung‐Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong‐Mu Sun, Jianhua Chen, Guohua Yu, Chen‐Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, for the RATIONALE-302 Investigators
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu, Lin Shen, Chunmei Bai, Wei Wang, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihebali Chi, Yongmei Yin, Wenhui Lou, Nong Xu, Yuxian Bai, Tao� Zhang, Dianrong Xiu, Xiuwen Wang, Ying Yuan, Jia Chen, Shukui Qin, Ru Jia, Ming Lu, Yuejuan Cheng, Zhiwei Zhou, Jing Li, James Jun He, Weiguo Su